HDAC2 and COVID-19: We conducted a case-control study to investigate the differential expression of DNMT1, DNMT3A, DNMT3B, HDAC2, and HDAC3 in the blood of 120 patients (30 mild, 30 moderate, 30 severe, and 30 critical) and 30 healthy subjects without COVID-19.